Traws Pharma
TRAW
9 hedge funds and large institutions have $4.44M invested in Traws Pharma in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 3 closing their positions.
28% more capital invested
Capital invested by funds: $3.46M → $4.44M (+$983K)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
10% less funds holding
Funds holding: 10 → 9 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$46.6K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$31K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$31K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$186K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$41K |
| 3 |
AIM
Acrospire Investment Management
Chicago,
Illinois
|
-$10K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCP
1
Tyndall Capital Partners
New York
| $1.58M | – | – | – |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $1.17M | -$186K | -12 | -15% |
|
|
BC
3
Boxer Capital
San Diego,
California
| $962K | – | – | – |
|
4
Renaissance Technologies
New York
| $368K | – | – | – |
|
|
5
Vanguard Group
Malvern,
Pennsylvania
| $169K | +$31K | +2 | +25% |
|
|
WMSA
6
Weiss Multi-Strategy Advisers
New York
| $68K | – | – | – |
|
|
BCM
7
Bridgeway Capital Management
Houston,
Texas
| $51K | +$46.6K | +3 | New |
|
|
VKH
8
Virtu KCG Holdings
New York
| $36K | – | – | – |
|
|
PAM
9
Panagora Asset Management
Boston,
Massachusetts
| $26K | +$31K | +2 | New |
|
10
Morgan Stanley
New York
| $4K | – | – | – |
|
|
HFM
11
Hartford Financial Management
Hartford,
Connecticut
| $3K | – | – | – |
|
12
Creative Planning
Overland Park,
Kansas
| $2K | – | – | – |
|
13
BlackRock
New York
| $1K | – | – | – |
|
14
Citigroup
New York
| $1K | – | – | – |
|
|
15
Citadel Advisors
Miami,
Florida
| – | -$41K | -3 | Closed |
|
|
AIM
16
Acrospire Investment Management
Chicago,
Illinois
| – | -$10K | -1 | Closed |
|
|
17
UBS Group
Zurich,
Switzerland
| – | -$7K | -1 | Closed |
|
TRAW Hedge Fund Activity: Q1 2017 in Review
9 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q1 2017, worth a combined $4.44M — up 28% from $3.46M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of TRAW and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $46.6K. The largest seller was Sabby Management, cutting an estimated $186K.
- 9 institutional investors held Traws Pharma (TRAW) as of Q1 2017, down from 10 in Q4 2016.
- Funds reported $4.44M of Traws Pharma stock for Q1 2017, up 28% quarter-over-quarter.
- 2 funds opened new Traws Pharma positions in Q1 2017 and 3 closed out, a net change of -1 holder.
- The largest Traws Pharma buyer in Q1 2017 was Bridgeway Capital Management, an estimated $46.6K added.
- The largest Traws Pharma seller in Q1 2017 was Sabby Management, an estimated $186K sold.
Based on aggregated 13F filings for Q1 2017.